Shares of Mylan NV MYL tumbled nearly 20 percent on Thursday after the company announced a massive $7.2 billion acquisition of Meda, a Sweden-based drugmaker.
The stock's plunge likely prompted Vetr top raters to upgrade Mylan's stock rating to a five star out of five-star rating. In fact, shares of Mylan have risen to $41.42 since the prior rating of four stars was issued 16 days ago.
Related link: Here's how crowdsourced ratings can beat the market.
In addition to an upgrade to clear bull territory, 87 percent of the crowd's ratings are bullish and the crowd sourced price target of $54.62 implies a potential upside of more than 30 percent.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
